Market cap
₹93 Cr
Revenue (TTM)
₹28 Cr
P/E Ratio
87.9
P/B Ratio
11.4
Div. Yield
0 %
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
93 | 71 | 37 | 28,304 | 21,511 |
Revenue (₹ Cr) |
28 | 1 | 30 | 5,595 | 1,296 |
Net Profit (₹ Cr) |
1.06 | 1.56 | 3.89 | 859.32 | 249.23 |
Net Margin (%) |
3.31 | 70.74 | 11.98 | 14.81 | 18.88 |
RoE (%) |
-- | 3.45 | 9.24 | 17.37 | 9.98 |
Price to Earnings |
87.92 | 45.58 | 9.65 | 33.11 | 86.31 |
Price-To-Book |
11.44 | 1.56 | 0.87 | 5.51 | 8.29 |
Income Statement (₹ Cr)
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Operating Revenue
|
27.56 | 1.47 | 30.32 | 5,594.69 | 1,296.02 |
|
Total Income
|
31.92 | 2.21 | 32.43 | 5,801.47 | 1,320.11 |
|
Total Expenditure
|
29.84 | 0.29 | 26.52 | 4,507.47 | 889.54 |
|
EBITDA
|
-2.28 | 1.18 | 3.79 | 1,087.22 | 406.48 |
|
Depreciation
|
1.49 | 0.02 | 0.43 | 79.12 | 78.80 |
|
EBIT
|
-3.76 | 1.16 | 3.37 | 1,008.10 | 327.69 |
|
Interest
|
1.23 | 0.07 | 0.24 | 83.89 | 20.95 |
|
Other Income
|
4.36 | 0.74 | 2.11 | 206.78 | 24.09 |
|
Exceptional Items
|
0.00 | 0.00 | 0.00 | 0.00 | -3.66 |
|
Profit before Tax
|
-0.63 | 1.83 | 5.24 | 1,130.99 | 327.16 |
|
Provision for Tax
|
-1.69 | 0.27 | 1.35 | 271.67 | 77.93 |
|
Profit after Tax
|
1.06 | 1.56 | 3.89 | 859.32 | 249.23 |
Liabilities (₹ Cr)
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
9.37 | 45.52 | 43.25 | 5,135.22 | 2,593.77 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -4.49 | 0.00 |
|
Non-Current Liabilities
|
11.03 | 1.46 | 0.17 | 326.83 | 306.97 |
|
Current Liabilities
|
17.66 | 0.83 | 2.32 | 1,461.60 | 701.52 |
|
Total Liabilities
|
28.05 | 47.10 | 47.88 | 6,523.10 | 3,201.43 |
Assets (₹ Cr)
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
13.21 | 12.05 | 2.15 | 3,571.56 | 1,958.51 |
|
Current Assets
|
24.85 | 35.76 | 43.44 | 3,029.24 | 1,370.00 |
|
Total Assets
|
28.05 | 47.10 | 47.88 | 6,523.10 | 3,201.43 |
|
Total Debt*
|
12.06 | 0.90 | 1.81 | 766.57 | 441.66 |
|
Net Current Assets
|
7.19 | 34.93 | 41.12 | 1,567.64 | 668.48 |
|
Contingent Liabilities
|
-- | 0.41 | 1.09 | 34.20 | 18.84 |
Cashflow (₹ Cr)
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-2.36 | -0.04 | -1.58 | 382.01 | 142.38 |
|
Cash Flow from Investing Activities
|
-0.90 | -25.03 | 2.01 | -963.81 | -619.38 |
|
Cash from Financing Activities
|
3.81 | -0.07 | -3.44 | 590.26 | 243.86 |
|
Net Cash Inflow / Outflow
|
0.56 | -25.15 | -3.01 | 8.45 | -233.14 |
Ratios
Profitability Ratios
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-76.70 | 0.74 | 20.17 | 22.42 | 11.65 |
|
ROE (%)
|
0.00 | 3.45 | 9.24 | 17.37 | 9.98 |
|
ROA (%)
|
3.80 | 3.33 | 8.28 | 13.76 | 7.73 |
|
EBIT Margin (%)
|
-13.66 | 79.18 | 11.10 | 18.02 | 25.28 |
|
Net Margin (%)
|
3.31 | 70.74 | 11.98 | 14.81 | 18.88 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
76.89 | 261.18 | -8.02 | 25.31 | 30.04 |
|
EBIT Growth (%)
|
-24.39 | 225.43 | -7.20 | 15.74 | 26.63 |
|
Net Profit Growth (%)
|
122.34 | 277.30 | -14.22 | 31.78 | 28.03 |
|
EPS Growth (%)
|
125.49 | 671.12 | -14.22 | 27.56 | 24.20 |
|
Book Value Growth (%)
|
-154.12 | 0.41 | 14.95 | 29.40 | 10.33 |
Valuation Ratios
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 45.58 | 9.65 | 33.11 | 85.31 |
|
Price / Book Value
|
-1.55 | 1.56 | 0.87 | 5.51 | 8.29 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 1.70 | 0.14 | 0.00 |
|
EV/EBITDA
|
-6.14 | 60.83 | 9.03 | 25.95 | 53.99 |
|
Market Cap (₹ Cr)
|
10.64 | 74.45 | 33.58 | 22,270.68 | 14,525.20 |
Solvency Ratios
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.18 | 0.02 | 0.00 | 0.00 | 0.08 |
|
Short term debt to equity ratio
|
-- | -- | 0.03 | 0.16 | 0.18 |
|
Current Ratio
|
1.41 | 43.09 | 18.71 | 2.07 | 1.95 |
|
Quick Ratio
|
1.13 | 43.09 | 18.70 | 1.52 | 0.93 |
|
Interest Coverage
|
0.49 | 25.70 | 22.64 | 14.48 | 16.62 |
Operating Efficiency Ratios
| Parmax Pharma | IEL | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
41.75 | 0.00 | 6.02 | 18.34 | 30.12 |
|
Asset Turnover
|
0.99 | 0.03 | 0.65 | 0.90 | 0.40 |
|
Receivable days
|
66.89 | 71.30 | 59.31 | 52.05 | 106.76 |
|
Inventory Days
|
168.22 | 0.00 | 17.38 | 52.79 | 146.98 |
|
Payable days
|
453.49 | -- | 59.34 | 38.65 | 103.88 |
|
Cash Conversion Cycle
|
-218.39 | -- | 17.35 | 66.19 | 149.86 |